Maxion Therapeutics Highly Commended in ‘Employer of the Year’ Category at Cambridge Independent Science and Technology Awards
Cambridge, UK – 6 June 2024
Maxion Therapeutics is pleased to announce it has been recognised as ‘Highly Commended’ in the ‘Employer of the Year’ category at the Cambridge Independent Science and Technology Awards 2024. The category recognises organisations in any field of science and technology that are attractive places to work, with a commitment to its team, corporate responsibility and the green agenda – truly supporting its employees and community.
Director of Operations Sylwia Mankowska attended the ceremony on 16th May at Hinxton Hall, Wellcome Genome Campus, Cambridgeshire with a group of representatives (Mark Bushell, Director of Technology, Pedro Villar, Associate Principal Scientist, and Edward Humphries, Principal Scientist).
She commented:
“At Maxion, we try to ensure that everyone feels valued and supported, blending complementary skills harmoniously and efficiently. We are proud to be values-driven, with a company ethos that prioritises integrity, respect, and collaboration in a friendly and welcoming atmosphere. We’re therefore very pleased to be recognised with this special acknowledgement.”
Sylwia Mankowska, Director of Operations
Dr. Arndt Schottellius, CEO, said:
We are delighted to be Highly Commended at this year’s Cambridge Independent Science and Technology Awards in the ‘Employer of the Year’ category
Arndt Schottellius, CEO
Maxion Therapeutics team.
Dr Arndt Schottelius said: “At Maxion, we are actively pursuing world-class science, with a strong entrepreneurial spirit that runs through the entire organisation - no matter the role. Since joining Maxion in March, I’ve be impressed by how our senior leadership enables and empowers the team to achieve its goals with close alignment. This is especially fundamental as we work towards changing the therapeutic landscape for autoimmune and chronic pain patients worldwide, progressing best-in-class and first-in-class candidates, based upon our Knotbody® technology, ever closer towards the clinic.”
Last year, Maxion grew its team from 8 to 28 people following its pre-Series A fundraise - successfully attracting talent from around the world with a 50/50 gender split and sponsoring two Global Talent Visas. The company is also committed to nurturing future talent through its student placement programme.
Maxion’s scientists, from junior through to senior roles, are regularly given the opportunity to present and participate in international conferences, providing valuable exposure and networking opportunities. Its flexible working arrangements and enhanced maternity and paternity leave policies enable employees to achieve a healthy work-life balance.
The company is also deeply committed to corporate social responsibility and the green agenda. It actively participates in the Green Impact Scheme, an award-winning United Nations programme designed to support environmentally and socially sustainable practices. Its efforts to sustainability were recognised last year with a Bronze award.
News
